Alumis Inc.
Every calculator, already run for ALMS
Open the full toolkit →You have the numbers on ALMS. Get the argument.
A written report on which of these readings actually decide the outcome for Alumis Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering ALMSAnalyst Price Target Disagreement for Alumis Inc.
Wall Street's bull case implies +542% from the current price; the bear case implies +109%. A 433% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ALMS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and c…
ALMS — frequently asked
Is ALMS a buy right now?
Wall Street's consensus rating on Alumis Inc. is Strong Buy across 10 analysts, with a mean price target of $32.13 (+349% vs. the current $7.16). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ALMS's next earnings date?
Alumis Inc. is next scheduled to report earnings around Nov 12, 2026. A full ALMS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Alumis Inc.?
Analysts covering Alumis Inc. (ALMS) range from a bear-case target of $15.00 to a bull-case high of $46.00, with a mean consensus target of $32.13 across 8 analysts. The spread of $31.00 (433% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Alumis Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Alumis Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALMS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Alumis Inc., in minutes. 3 free reports included with every account — no credit card required.